4D Molecular Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the 2021 Annual Meeting of Stockholders held by 4D Molecular Therapeutics, Inc. on May 17, 2021. The meeting was conducted virtually via the internet. As of the record date on March 26, 2021, there were 26,694,379 shares of common stock outstanding.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and voting results.
Material Changes and Voting Results
A total of 16,717,561 shares were voted in person or by proxy. The following proposals were approved:
- Proposal 1 (Election of Directors): Stockholders elected Class I director nominees David Kirn, M.D., and David Schaffer, Ph.D., to serve until the 2024 Annual Meeting.
- Proposal 2 (Ratification of Auditors): Stockholders ratified the selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2021.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Confirmation of the election of David Kirn, M.D., and David Schaffer, Ph.D., to the Board of Directors.
- Verification of PricewaterhouseCoopers LLP as the independent auditor for fiscal year 2021.
- Total shares voted: 16,717,561 out of 26,694,379 outstanding.
- Vote counts for Proposal 2: 16,698,132 For, 18,996 Against, 433 Abstain.